JW THERAP-B Plans to Issue Approximately 61.1855 Million Subscription Shares at a Discount of About 2.97% to Raise HK$160 Million

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Zhitong Finance APP reports: JW THERAP-B (02126) announced that on November 15, 2026, the company entered into subscription agreements with China Hongqiao Holdings Limited or its designated entities and Novo Vista Limited Partnership. It plans to issue a total of approximately 61.1855 million subscription shares to them at HK$2.615 per share. This price represents a discount of approximately 2.97% compared to the closing price of HK$2.695 per share quoted on the Stock Exchange of Hong Kong on the last trading day. The total subscription amount is HK$160 million.

The company intends to use the net proceeds from the subscription for the following purposes: approximately 40% will be used to advance the R&D of the group's in vivo CAR-T product pipeline (including JWCAR306 and other candidate products), covering investigator-initiated trials (IIT), manufacturing process development and optimization, IND-enabling studies, and other related R&D activities; approximately 30% will be used to support the R&D of the group's autologous CAR-T product pipeline (including JWCAR201 and JWCAR239, a dual-target, dual-armored CD19/CD20 CAR-T candidate product), focusing on advancing ongoing and planned clinical studies, generating clinical data, conducting IND-enabling studies, and optimizing manufacturing processes; approximately 20% will be used to support the continuous development and upgrading of the group's technology platform and manufacturing capabilities, including the purchase, replacement, and upgrading of manufacturing and laboratory equipment, as well as improvements to existing manufacturing facilities and related infrastructure; and approximately 10% will be used to support the group's working capital needs and general corporate purposes.

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings